ConvaTec Group PLC

CTEC: XLON (GBR)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
GBX 727.00ZqrmjFgvgclhm

Convatec Earnings: Steady Operational Improvements Have Goosed Growth in 2024

Convatec’s results for the first half of 2024 displayed continued improvement. The firm remains on track to meet our full-year expectations, so we’re leaving our fair value estimate unchanged. Thanks to its focus on operations, commercialization of pipeline products, and emphasis on chronic care products, Convatec has steadily and incrementally pushed growth and profitability higher. We’ve long believed that Convatec’s switching costs among end users and the potential to introduce novel products were enough to provide the firm with a narrow moat. Under CEO Karim Bitar, the firm has begun to realize that potential and make good on its moat.

Sponsor Center